Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 21, 2020
Daily News
February 21, 2020
- MHLW Has to Decide Which Bureau Will Lead Formulary Push: Pharmacy Officer
February 21, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
- Astellas, MSD Follow Suit to Boost Measures to Protect Employees from Coronavirus Infection
February 21, 2020
- Takeda Vaults to 9th in Global Pharma Ranking after Shire Buy, Roche Tops List: Jiho Tally
February 21, 2020
- AMED to Fund Development of Coronavirus Diagnostics, Treatments, and Vaccines by NIID, Univ. of Tokyo
February 21, 2020
- Kyowa Kirin Initiates Japan PI Trial of Automated Injection Device for G-Lasta
February 21, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…